一心堂药业集团关于使用部分暂时闲置2018年可转债募集资金进行现金管理的进展公告
要点综述
- 一心堂药业集团股份有限公司（以下简称“一心堂”或“公司”，股票代码：002727）于2026年5月20日召开2025年年度股东大会，通过了使用不超过3亿元人民币的2018年公开发行可转换公司债券（可转债）暂时闲置募集资金进行现金管理的议案。
- 资金管理方式包括但不限于购买一年期以内的固定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款和协定存款等。
- 公司本次现金管理由全资子公司鸿翔中药有限公司与上海浦东发展银行昆明分行签订结构性存款合同，认购金额为2,500万元，产品为3个月早鸟款保本浮动收益型，保底年收益率0.70%，浮动收益率最高至1.15%。
对股东及股价可能产生影响的事项
- 现金管理提升资金使用效率：通过适度的低风险现金管理，公司可在不影响募投项目正常开展的前提下提升资金使用效率，增加投资收益，提升公司整体业绩水平，为股东带来更多投资回报。
- 风险可控、信息充分披露：公司已制定多项风险控制措施，包括严格的审批流程、财务和内审部门的实时跟踪和监督、独立董事及保荐机构的监督，以及根据深交所规定的及时信息披露，有效保障资金安全。
- 产品为低风险理财，收益稳健：所选理财均为保本浮动收益型结构性存款，历史产品最低保底收益率0.70%，最高浮动收益率达1.45%，风险极低。
- 滚动使用、灵活管理：3亿元额度可滚动使用，董事长获授权可具体办理相关事项，公司可根据金融市场变化灵活调整投资策略。
- 近12个月现金管理明细：公司及下属子公司过去一年内多次进行同类现金管理，涉及金额从1,000万元至8,900万元不等，多数产品已到期收回，收益稳定，部分产品尚未到期。
详细内容
公司本次新投资由全资子公司鸿翔中药有限公司于2026年5月25日投资2,500万元于上海浦东发展银行的结构性存款产品，期限三个月，为保本浮动收益型产品。产品保底年化收益率为0.70%，浮动收益率区间为0%/0.95%/1.15%，收益率视市场波动及银行测算结果而定。
公司强调此次现金管理产品为低风险投资品种，但仍面临金融市场波动、实际收益不可预期、操作及监控等风险。公司已出台多项风险控制措施，包括：
1. 履行完备审批手续，签署正式合同文件，由财务负责人组织实施；
2. 财务部人员实时分析、跟踪产品投向和进展，评估风险，及时应对；
3. 内审部门、独立董事、审计委员会及保荐机构多重监督，必要时可聘请第三方机构专项审计；
4. 按深交所要求及时充分信息披露，保障投资者知情权。
过去12个月现金管理回顾：
- 公司及下属子公司累计投资金额较大，单笔最大8,900万元，多数已到期收回，年化收益率区间0.7%~1.45%。
- 全部为保本浮动收益型结构性存款，银行为上海浦东发展银行昆明分行。
- 当前仍有部分产品在投，期限多为3-6个月，收益稳定。
此外，公司已准备好所有相关合同及深交所要求的文件备查。
投资者关注要点与可能的股价影响
- 此次公告显示公司对募集资金的高效管理和稳健投资策略，有助于提升资金使用效率与公司整体业绩，预计对公司长期盈利能力和现金流有正面影响。
- 公告无重大不确定性及异常风险，所有投资均为低风险理财产品，短期内不会对募投项目造成影响。
- 资金管理透明合规，内部控制健全，信息披露充分，有助于提升投资者信心。
- 若未来金融市场波动加剧，实际收益或有变化，需持续关注公司后续披露。
免责声明
本文仅为新闻报道，不构成任何投资建议。投资者据此操作，风险自负。
English Version
Yixintang Pharmaceutical: Update on Utilization of Idle Proceeds from 2018 Convertible Bond for Cash Management
Key Highlights
- Yixintang Pharmaceutical Group Co., Ltd. (Stock code: 002727, “the Company”) held its 2025 Annual Shareholders’ Meeting on May 20, 2026, and approved the proposal to use up to RMB 300 million of idle funds raised from its 2018 convertible bond for cash management.
- Cash management includes but is not limited to purchasing fixed-income or principal-guaranteed floating-income financial products with maturities under one year, large-denomination certificates of deposit, regular deposits, call deposits, and agreement deposits.
- The latest investment: Wholly-owned subsidiary Hongxiang Traditional Chinese Medicine Co., Ltd. signed a structured deposit contract with SPD Bank Kunming Branch, subscribing RMB 25 million, 3-month principal-guaranteed floating-income product, with a minimum annual yield of 0.70% and a maximum floating yield up to 1.15%.
Potentially Price-Sensitive Information for Shareholders
- Improved Fund Utilization Efficiency: By using low-risk cash management, the Company increases the efficiency of idle funds without affecting ongoing investment projects, potentially boosting returns and overall performance for shareholders.
- Controlled Risk, Full Disclosure: The Company has set up comprehensive risk controls, including rigorous approval procedures, real-time monitoring by the finance and audit teams, oversight by independent directors and the sponsor institution, and timely disclosure per Shenzhen Stock Exchange requirements.
- Low-Risk Products, Stable Returns: All investments are in principal-guaranteed floating-income structured deposits, with past products yielding from 0.70% (minimum) to 1.45% (maximum), reflecting very low risk.
- Flexible, Rolling Use: The RMB 300 million limit can be rolled over, with the Chairman authorized for specific execution. The Company can dynamically adjust investment strategies based on market changes.
- Comprehensive Record of Recent Transactions: Over the past 12 months, the Company and subsidiaries have made multiple similar investments, with single products ranging from RMB 10 million to RMB 89 million, most already matured and repaid with stable returns.
Details
The current investment is made through the wholly-owned subsidiary Hongxiang Traditional Chinese Medicine Co., Ltd., investing RMB 25 million on May 25, 2026, in a 3-month principal-guaranteed floating-yield structured deposit at SPD Bank. The product offers a minimum annualized yield of 0.70%, with floating yields at 0.95% or 1.15% depending on market conditions.
The Company reiterates these products are low-risk but subject to market fluctuations, actual yields may vary. Risks are mitigated by:
1. Fully completed approval process, formal contracts signed and implemented by the finance head;
2. Real-time tracking and risk assessment by the finance department, with timely risk responses;
3. Internal audit, independent directors, audit committee, and sponsor supervision, with third-party audits as needed;
4. Timely, transparent disclosure as required by the Shenzhen Stock Exchange.
Recent Cash Management Review (Past 12 Months):
- Total investments by the Company and subsidiaries have been substantial, with most products already matured and repaid, annualized yields from 0.7% to 1.45%.
- All products purchased from SPD Bank Kunming Branch.
- Some products are still active, mostly with 3-6 month terms and stable returns.
All related contracts and documentation are on file as required by the Shenzhen Stock Exchange.
Investor Focus and Potential Share Price Impact
- The announcement demonstrates the Company’s efficient and prudent management of idle funds, likely to improve earnings and cash flows, and thus could have a positive long-term effect on share price.
- No significant uncertainties or abnormal risks are disclosed; all investments are low risk and do not affect ongoing fundraising projects.
- Transparent, compliant fund management and robust internal control are likely to boost investor confidence.
- Future actual returns may fluctuate with market dynamics; investors should monitor subsequent disclosures.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should make decisions at their own risk.
